

22 Mar 2018 | Interviews

QUOTED. March 22, 2018. Katarzyna Mazur-Hofsäss.

by

The head of Zimmer Biomet's EMEA division, Katarzyna Mazur-Hofsäss, is concerned about how the EU's new Medical Device and IVD Regulations will affect the market there. Check out what she said here.

"Europe used to have an advantage [over other geographies] in that the path to market here for innovation was faster, without there having been any – in my strong opinion – negative impact on patient safety. But this is changing with the new regulations. This advantage is disappearing and, together with the lower pricing and much more fragmented nature of the market, it makes Europe that little bit less attractive, and it matters." –Katarzyna Mazur-Hofsäss, EMEA president, Zimmer Biomet

- Find out more: [Exec Chat: Zimmer Biomet's EMEA Head On Facing The New Reality In Health Care](#)

[Click here](#) for a free trial of *Medtech Insight*